UC San Francisco Electronic Theses and Dissertations

Total Page:16

File Type:pdf, Size:1020Kb

UC San Francisco Electronic Theses and Dissertations UCSF UC San Francisco Electronic Theses and Dissertations Title The genetics of splicing in cancer Permalink https://escholarship.org/uc/item/0sr370mt Author Chen, Justin Publication Date 2014 Peer reviewed|Thesis/dissertation eScholarship.org Powered by the California Digital Library University of California Copyright 2014 by Justin W. Chen ii To the most incredible women in my life: Alana, Darlene, and Yvonne iii ACKNOWLEDGEMENTS This work could not have been done without the assistance and support from countless people, some of whom I’d like to thank here. First and foremost, is my thesis adviser, Bill Weiss. Bill has constantly encouraged me to follow the data and has never tried to pigeon‐hole me into a particular project or avenue of thought. His support has allowed me to explore problems and pose my own solutions to questions I was interested in, and not just what interested him. I owe my growth as a scientist directly to his mentorship. Similarly, my thesis committee members Davide Ruggero and Joe Costello have dispensed helpful advice throughout my graduate career as they both served on my qualifying committee, and Joe was gracious enough to let spend a quarter in his lab as a rotation student. Many Weiss Lab members, both past and present, have contributed directly and indirectly to my thesis. Chris Hackett got the ball rolling before I was even thinking about graduate school by setting up the modifier screen and harvesting tissues. Chris was a great example of what a graduate student should strive to be, and I have tried to emulate him whenever possible. Clay Gustafson has been a tremendous colleague and mentor as well. Even though we work on drastically different projects, he has been very generous with his time and has made a strong effort to think critically about experimental difficulties I’ve faced along the way. Along with Chris, I have enjoyed commiserating with my fellow graduate students in the lab, Jasmine Lau and Justin Meyerowitz. Christine Cheng and Robyn Wong have been a big help whenever I’ve needed a little technical assistance. I’ve also been fortunate enough to be able to pick the brains of several scientists who have come through the lab: Miller Huang, Shirin Ilkhanizadeh, Anders Persson, Erin Simonds, and Fredrik Swartling. iv Scientists outside of the lab have made a fantastic support group throughout the years. Kasia Skrzypczynska has remained a steadfast neighbor in the outer sunset, and Robyn Mills, Julie VanderMeer, and Mike Sachs have been terrific friends. Stacy Musone and Bani Tamraz were the first grad students I got to know before I even knew I wanted to go to grad school, and we’ve kept in touch over the years. I also probably would not have gone to grad school had Pui Kwok not taken a chance on hiring me as a technician in his lab and in the process reinvigorating my interest in science. My co‐ed basketball team, Busta Buckets, never quite made it to the playoffs, but I’ve enjoyed my time on the hardcourt with fellow BMSers (and affiliates) Leonard Chavez, Nicole and Ian Galloway, Karen Ring, Noelle Huskey, Krister Barkovich, Lionel Lim, and Pankaj Sahai. There’s nothing like escaping the lab like getting destroyed in the paint! I cannot thank my family (and my near‐family, Ken) too much for all of the support they have afforded me throughout the years. My sister Darlene, a fantastic immunologist in her own right, has been a wonderful scientific sounding board despite our disparate scientific backgrounds. I am supremely fortunate to have been able to meet, date, and marry my wife Alana during graduate school. She has been completely understanding of the long hours and random scientific conversations that sometimes occur when we’re in the presence of other scientists. Together, we have a wonderful dog, a Golden‐Retriever and Yellow Labrador mix named Starbuck who never fails to greet me with a wagging tail. She is the best remedy for a long day in the lab. v CONTRIBUTIONS Chapter 1 is taken directly from a manuscript written as a review and has been published online in advance of print: Chen J and Weiss WA. “Alternative Splicing in Cancer: Implications for Biology and Therapy.” Oncogene. Advance Online Publication (2014) doi:10.1038/onc.2013.570 Chapters 2 and 4 are taken from a manuscript that is currently in submission: “The Genetics of Splicing in Neuroblastoma” by Justin Chen, Christopher S. Hackett, Shile Zhang, Young K. Song, Robert J.A. Bell, Annette Molinaro, David A. Quigley, Allan Balmain, Jun S. Song, Joseph F. Costello, W. Clay Gustafson, Terry Van Dyke, Pui‐Yan Kwok, Javed Khan, and William A. Weiss. Chapter 3 is modified from this same manuscript: Christopher Hackett set up the initial backcrossed modifier screen and harvested the SCG and CB. He also genotyped the mice with the help of Pui‐Yan Kwok’s lab and ran exon arrays on the SCG with the assistance of Young Song in Javed Khan’s lab with arrays provided by Terry Van Dyke. David Quigley in Allan Balmain’s lab provided the eQTL software used in this analysis. Shile Zhang provided RNA‐Seq data on human neuroblastoma patients. Rob Bell in Jun Song's lab provided somatic mutation calls from TCGA GBM samples and ran my scripts on the germline variants. Annette Molinaro provided statistical support. Clay Gustafson provided helpful experimental insights and William Weiss oversaw the project. I have performed all other experiments and wrote the manuscript. vi ABSTRACT Alternative splicing plays critical roles in normal development and can promote growth and survival in cancer. Genes that have canonical splice variants that function antagonistically can be ectopically expressed to drive malignant progression. Additionally, aberrant splicing, the production of noncanonical and cancer‐specific mRNA transcripts, can lead to loss‐of‐function in tumor suppressors or activation of oncogenes and cancer pathways. Emerging data suggests that aberrant splicing products and loss of canonically spliced variants correlate with stage and progression in malignancy. Not only do these data illuminate roles for alternative splicing in cancer and intersections between alternative splicing pathways and therapy, but they illustrate the importance of understanding the genetic basis of splicing. Using a transgenic model of neuroblastoma, we set up a backcrossed genetic system to derive distinct virtual genomes of over 100 individual mice in which we have profiled exon expression in two different neural tissues. We identified splicing quantitative trait loci (sQTL) which map genetic control of splicing and define key splicing motifs. We identify these motifs as sites of recurrent somatic mutations in cancer. We also use this analysis to identify novel effector splicing events. Among these, we show that a triplet splicing event within FUBP1 modulates levels of the MYC oncoprotein in human neuroblastoma‐derived cell line, and correlates with outcome in neuroblastoma. vii TABLE OF CONTENTS ACKNOWLEDGEMENTS ................................................................................................................ iv CONTRIBUTIONS ........................................................................................................................ vi ABSTRACT ................................................................................................................................. vii TABLE OF CONTENTS ................................................................................................................... viii LIST OF TABLES .......................................................................................................................... ix LIST OF FIGURES ......................................................................................................................... x CHAPTER 1: INTRODUCTION ........................................................................................................ 1 CHAPTER 2: THE GENETICS OF SPLICING IN NEUROBLASTOMA .......................................................... 29 CHAPTER 3: DISCUSSION AND CONCLUSIONS ................................................................................. 50 CHAPTER 4: MATERIALS AND METHODS ....................................................................................... 55 REFERENCES ............................................................................................................................... 67 APPENDICES ............................................................................................................................... 85 LIBRARY RELEASE ....................................................................................................................... 176 viii LIST OF TABLES TABLE 2.1: RECURRENT GENES WITH SPLICING MOTIF MUTATIONS ................................................... 42 TABLE 4.1: GENOTYPING MARKERS ............................................................................................... 62 APPENDIX A: CB CIS‐SQTL ........................................................................................................... 85 APPENDIX B: SCG CIS‐SQTL ......................................................................................................... 121 APPENDIX C: TRANS‐SQTL ........................................................................................................... 160 APPENDIX D: DIFFERENTIALLY EXPRESSED GENES ON CHR 10 BETWEEN RS13480474 AND RS38621064 168 APPENDIX E: DIFFERENTIALLY EXPRESSED GENES ON CHR X BETWEEN RS33478059 AND RS13483805 169 APPENDIX
Recommended publications
  • 4-6 Weeks Old Female C57BL/6 Mice Obtained from Jackson Labs Were Used for Cell Isolation
    Methods Mice: 4-6 weeks old female C57BL/6 mice obtained from Jackson labs were used for cell isolation. Female Foxp3-IRES-GFP reporter mice (1), backcrossed to B6/C57 background for 10 generations, were used for the isolation of naïve CD4 and naïve CD8 cells for the RNAseq experiments. The mice were housed in pathogen-free animal facility in the La Jolla Institute for Allergy and Immunology and were used according to protocols approved by the Institutional Animal Care and use Committee. Preparation of cells: Subsets of thymocytes were isolated by cell sorting as previously described (2), after cell surface staining using CD4 (GK1.5), CD8 (53-6.7), CD3ε (145- 2C11), CD24 (M1/69) (all from Biolegend). DP cells: CD4+CD8 int/hi; CD4 SP cells: CD4CD3 hi, CD24 int/lo; CD8 SP cells: CD8 int/hi CD4 CD3 hi, CD24 int/lo (Fig S2). Peripheral subsets were isolated after pooling spleen and lymph nodes. T cells were enriched by negative isolation using Dynabeads (Dynabeads untouched mouse T cells, 11413D, Invitrogen). After surface staining for CD4 (GK1.5), CD8 (53-6.7), CD62L (MEL-14), CD25 (PC61) and CD44 (IM7), naïve CD4+CD62L hiCD25-CD44lo and naïve CD8+CD62L hiCD25-CD44lo were obtained by sorting (BD FACS Aria). Additionally, for the RNAseq experiments, CD4 and CD8 naïve cells were isolated by sorting T cells from the Foxp3- IRES-GFP mice: CD4+CD62LhiCD25–CD44lo GFP(FOXP3)– and CD8+CD62LhiCD25– CD44lo GFP(FOXP3)– (antibodies were from Biolegend). In some cases, naïve CD4 cells were cultured in vitro under Th1 or Th2 polarizing conditions (3, 4).
    [Show full text]
  • Download Download
    Supplementary Figure S1. Results of flow cytometry analysis, performed to estimate CD34 positivity, after immunomagnetic separation in two different experiments. As monoclonal antibody for labeling the sample, the fluorescein isothiocyanate (FITC)- conjugated mouse anti-human CD34 MoAb (Mylteni) was used. Briefly, cell samples were incubated in the presence of the indicated MoAbs, at the proper dilution, in PBS containing 5% FCS and 1% Fc receptor (FcR) blocking reagent (Miltenyi) for 30 min at 4 C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL (Coulter Electronics Inc., Hialeah, FL, USA) flow cytometer. only use Non-commercial 1 Supplementary Table S1. Complete list of the datasets used in this study and their sources. GEO Total samples Geo selected GEO accession of used Platform Reference series in series samples samples GSM142565 GSM142566 GSM142567 GSM142568 GSE6146 HG-U133A 14 8 - GSM142569 GSM142571 GSM142572 GSM142574 GSM51391 GSM51392 GSE2666 HG-U133A 36 4 1 GSM51393 GSM51394 only GSM321583 GSE12803 HG-U133A 20 3 GSM321584 2 GSM321585 use Promyelocytes_1 Promyelocytes_2 Promyelocytes_3 Promyelocytes_4 HG-U133A 8 8 3 GSE64282 Promyelocytes_5 Promyelocytes_6 Promyelocytes_7 Promyelocytes_8 Non-commercial 2 Supplementary Table S2. Chromosomal regions up-regulated in CD34+ samples as identified by the LAP procedure with the two-class statistics coded in the PREDA R package and an FDR threshold of 0.5. Functional enrichment analysis has been performed using DAVID (http://david.abcc.ncifcrf.gov/)
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,309,565 B2 Kelly Li, San
    US0093 09565B2 (12) United States Patent (10) Patent No.: US 9,309,565 B2 BrOOmer et al. (45) Date of Patent: Apr. 12, 2016 (54) KARYOTYPING ASSAY 4,889,818. A 12/1989 Gelfand et al. 4,965,188 A 10, 1990 Mullis et al. (75) Inventors: Adam Broomer, Carlsbad, CA (US); 5.835 A RE E. tal Kelly Li, San Jose, CA (US), Andreas 3.66: A 56, RI. R. Tobler, Fremont, CA (US); Caifu 5.436,134. A 7/1995 Haugland et al. Chen, Palo Alto, CA (US); David N. 5,487.972 A 1/1996 Gelfand et al. Keys, Jr., Oakland, CA (US) 5,538,848. A 7/1996 Livak et al. s s 5,618,711 A 4/1997 Gelfand et al. (73) Assignee: Life Technologies Corporation, 5,677,1525,658,751 A 10/19978, 1997 Yues et. al. al. Carlsbad, CA (US) 5,723,591 A 3/1998 Livak et al. 5,773.258 A 6/1998 Birch et al. (*) Notice: Subject to any disclaimer, the term of this 5,789,224 A 8, 1998 Gelfand et al. patent is extended or adjusted under 35 38. A 3. 3. E. al U.S.C. 154(b) by 998 days. 5,854,033.sy w A 12/1998 LizardiCaO (ca. 5,876,930 A 3, 1999 Livak et al. (21) Appl. No.: 13/107,786 5,994,056. A 1 1/1999 Higuchi (22) Filed: May 13, 2011 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2011 FO281755A1 Nov. 17, 2011 EP OOTO685 A2 1, 1983 WO WO-2006/081222 8, 2006 Related U.S.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]
  • (WCPG): Poster Abstracts: Sunday
    ARTICLE IN PRESS JID: NEUPSY [m6+; October 2, 2018;12:59 ] European Neuropsychopharmacology (2018) 000, 1–75 www.elsevier.com/locate/euroneuro Abstracts of the 26th World Congress of Psychiatric Genetics (WCPG): Poster Abstracts: Sunday Sunday, October 14, 2018 with a 2kb upstream and 1kb downstream region was consid- ered for each gene. Gene-set analysis was conducted using MAGMA, with a principal components regression model for gene-based analyses. Sex, age, the 10 first and otherwise as- Poster Session III sociated principal components were included as covariates 4:00 p.m. - 6:00 p.m. in this step. We retrieved a “Hallmark Androgen response” gene-set from MSigDB to be tested in a case-control asso- SU1 ciation study. This gene-set contains 98 curated genes in- ANDROGEN RECEPTOR SIGNALING PATHWAYS IN- volved in the response to androgen receptor signaling. Also, FLUENCE IN ATTENTION-DEFICIT/HYPERACTIVITY a list of 534 annotated genes with at least one occurrence DISORDER of potential transcription factor binding sites (TFBS) for AR was created to investigate potential gene targets related to Djenifer Kappel 1, Bruna da Silva 1, Renata B. Cupertino 1, ADHD susceptibility. Diana Müller 1, Vitor Breda 2, Stefania Pigatto Teche 2, Results: No genome-wide association was observed at the Rogério Margis 1, Luis Augusto Rohde 2, Nina Roth Mota 3, SNPs or gene level. In the gene-set analysis, we found evi- Diego L. Rovaris 1, Eugênio H. Grevet 1, Claiton Bau 1 dence that the “Hallmark Androgen response” gene-set was significantly associated with ADHD susceptibility in our sam- 1 Universidade Federal do Rio Grande do Sul ple (p = 0.039).
    [Show full text]
  • Whole Exome Sequencing in Families at High Risk for Hodgkin Lymphoma: Identification of a Predisposing Mutation in the KDR Gene
    Hodgkin Lymphoma SUPPLEMENTARY APPENDIX Whole exome sequencing in families at high risk for Hodgkin lymphoma: identification of a predisposing mutation in the KDR gene Melissa Rotunno, 1 Mary L. McMaster, 1 Joseph Boland, 2 Sara Bass, 2 Xijun Zhang, 2 Laurie Burdett, 2 Belynda Hicks, 2 Sarangan Ravichandran, 3 Brian T. Luke, 3 Meredith Yeager, 2 Laura Fontaine, 4 Paula L. Hyland, 1 Alisa M. Goldstein, 1 NCI DCEG Cancer Sequencing Working Group, NCI DCEG Cancer Genomics Research Laboratory, Stephen J. Chanock, 5 Neil E. Caporaso, 1 Margaret A. Tucker, 6 and Lynn R. Goldin 1 1Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 2Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; 3Ad - vanced Biomedical Computing Center, Leidos Biomedical Research Inc.; Frederick National Laboratory for Cancer Research, Frederick, MD; 4Westat, Inc., Rockville MD; 5Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD; and 6Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA ©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135475 Received: August 19, 2015. Accepted: January 7, 2016. Pre-published: June 13, 2016. Correspondence: [email protected] Supplemental Author Information: NCI DCEG Cancer Sequencing Working Group: Mark H. Greene, Allan Hildesheim, Nan Hu, Maria Theresa Landi, Jennifer Loud, Phuong Mai, Lisa Mirabello, Lindsay Morton, Dilys Parry, Anand Pathak, Douglas R. Stewart, Philip R. Taylor, Geoffrey S. Tobias, Xiaohong R. Yang, Guoqin Yu NCI DCEG Cancer Genomics Research Laboratory: Salma Chowdhury, Michael Cullen, Casey Dagnall, Herbert Higson, Amy A.
    [Show full text]
  • Early Growth Response 1 Regulates Hematopoietic Support and Proliferation in Human Primary Bone Marrow Stromal Cells
    Hematopoiesis SUPPLEMENTARY APPENDIX Early growth response 1 regulates hematopoietic support and proliferation in human primary bone marrow stromal cells Hongzhe Li, 1,2 Hooi-Ching Lim, 1,2 Dimitra Zacharaki, 1,2 Xiaojie Xian, 2,3 Keane J.G. Kenswil, 4 Sandro Bräunig, 1,2 Marc H.G.P. Raaijmakers, 4 Niels-Bjarne Woods, 2,3 Jenny Hansson, 1,2 and Stefan Scheding 1,2,5 1Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden; 2Lund Stem Cell Center, Depart - ment of Laboratory Medicine, Lund University, Lund, Sweden; 3Division of Molecular Medicine and Gene Therapy, Department of Labora - tory Medicine, Lund University, Lund, Sweden; 4Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands and 5Department of Hematology, Skåne University Hospital Lund, Skåne, Sweden ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2019.216648 Received: January 14, 2019. Accepted: July 19, 2019. Pre-published: August 1, 2019. Correspondence: STEFAN SCHEDING - [email protected] Li et al.: Supplemental data 1. Supplemental Materials and Methods BM-MNC isolation Bone marrow mononuclear cells (BM-MNC) from BM aspiration samples were isolated by density gradient centrifugation (LSM 1077 Lymphocyte, PAA, Pasching, Austria) either with or without prior incubation with RosetteSep Human Mesenchymal Stem Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada) for lineage depletion (CD3, CD14, CD19, CD38, CD66b, glycophorin A). BM-MNCs from fetal long bones and adult hip bones were isolated as reported previously 1 by gently crushing bones (femora, tibiae, fibulae, humeri, radii and ulna) in PBS+0.5% FCS subsequent passing of the cell suspension through a 40-µm filter.
    [Show full text]
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Shear Stress Modulates Gene Expression in Normal Human Dermal Fibroblasts
    University of Calgary PRISM: University of Calgary's Digital Repository Graduate Studies The Vault: Electronic Theses and Dissertations 2017 Shear Stress Modulates Gene Expression in Normal Human Dermal Fibroblasts Zabinyakov, Nikita Zabinyakov, N. (2017). Shear Stress Modulates Gene Expression in Normal Human Dermal Fibroblasts (Unpublished master's thesis). University of Calgary, Calgary, AB. doi:10.11575/PRISM/27775 http://hdl.handle.net/11023/3639 master thesis University of Calgary graduate students retain copyright ownership and moral rights for their thesis. You may use this material in any way that is permitted by the Copyright Act or through licensing that has been assigned to the document. For uses that are not allowable under copyright legislation or licensing, you are required to seek permission. Downloaded from PRISM: https://prism.ucalgary.ca UNIVERSITY OF CALGARY Shear Stress Modulates Gene Expression in Normal Human Dermal Fibroblasts by Nikita Zabinyakov A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE GRADUATE PROGRAM IN BIOMEDICAL ENGINEERING CALGARY, ALBERTA JANUARY 2017 © Nikita Zabinyakov 2017 Abstract Applied mechanical forces, such as those resulting from fluid flow, trigger cells to change their functional behavior or phenotype. However, there is little known about how fluid flow affects fibroblasts. The hypothesis of this thesis is that dermal fibroblasts undergo significant changes of expression of differentiation genes after exposure to fluid flow (or shear stress). To test the hypothesis, human dermal fibroblasts were exposed to laminar steady fluid flow for 20 and 40 hours and RNA was collected for microarray analysis.
    [Show full text]
  • Effects of Proximal Tubule Shortening on Protein Excretion in a Lowe Syndrome Model
    BASIC RESEARCH www.jasn.org Effects of Proximal Tubule Shortening on Protein Excretion in a Lowe Syndrome Model Megan L. Gliozzi,1 Eugenel B. Espiritu,2 Katherine E. Shipman,1 Youssef Rbaibi,1 Kimberly R. Long,1 Nairita Roy,3 Andrew W. Duncan,3 Matthew J. Lazzara,4 Neil A. Hukriede,2,5 Catherine J. Baty,1 and Ora A. Weisz1 1Renal-Electrolyte Division, Department of Medicine, 2Department of Developmental Biology, and 3Department of Pathology, McGowan Institute for Regenerative Medicine, and Pittsburgh Liver Research Center, Pittsburgh, Pennsylvania; 4Department of Chemical Engineering, University of Virginia, Charlottesville, Virginia; and 5Center for Critical Care Nephrology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania ABSTRACT Background Lowe syndrome (LS) is an X-linked recessive disorder caused by mutations in OCRL,which encodes the enzyme OCRL. Symptoms of LS include proximal tubule (PT) dysfunction typically character- ized by low molecular weight proteinuria, renal tubular acidosis (RTA), aminoaciduria, and hypercalciuria. How mutant OCRL causes these symptoms isn’tclear. Methods We examined the effect of deleting OCRL on endocytic traffic and cell division in newly created human PT CRISPR/Cas9 OCRL knockout cells, multiple PT cell lines treated with OCRL-targeting siRNA, and in orcl-mutant zebrafish. Results OCRL-depleted human cells proliferated more slowly and about 10% of them were multinucleated compared with fewer than 2% of matched control cells. Heterologous expression of wild-type, but not phosphatase-deficient, OCRL prevented the accumulation of multinucleated cells after acute knockdown of OCRL but could not rescue the phenotype in stably edited knockout cell lines. Mathematic modeling confirmed that reduced PT length can account for the urinary excretion profile in LS.
    [Show full text]
  • Identification of Novel Genes in BRCA1-Regulated Pathways
    Identification of Novel Genes in BRCA1-Regulated Pathways DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Shweta Kotian, M.S. Graduate Program in Molecular, Cellular and Developmental Biology The Ohio State University 2013 Dissertation Committee: Professor Jeffrey D. Parvin, Advisor Professor Joanna L. Groden Professor Denis C. Guttridge Professor Mark R. Parthun Copyright by Shweta Kotian 2013 Abstract BRCA1 is an important breast- and ovarian-specific tumor suppressor gene. It is important in various cellular functions in the body including transcriptional regulation, cell cycle checkpoint activation, DNA damage response, and maintenance of genomic stability. Approximately 40% of hereditary breast cancers have mutations in BRCA1 or BRCA2, and it is unclear how the remaining cases are caused, presumably by mutations or in the alteration of expression of unknown genes. We hypothesize that these unknown genes or ‘missing BRCAs’ can be identified by bio-informatics methods. Performing gene co-expression analysis, we have compared the expression profiles of hundreds of genes across publicly available breast cancer microarray datasets, with those of BRCA1 and BRCA2. We propose that the genes, whose expression is highly correlated with BRCA1 and BRCA2, might function together in the same pathways. They could also potentially interact with each other. The main aim of this study is to identify these genes, and then biologically validate them in functional BRCA1-regulated pathways including homologous recombination and centrosome duplication. We also hope to find any mechanistic ii associations between these genes and BRCA1. Eventually, we hope to evaluate if these genes contribute to the process of carcinogenesis.
    [Show full text]
  • Nº Ref Uniprot Proteína Péptidos Identificados Por MS/MS 1 P01024
    Document downloaded from http://www.elsevier.es, day 26/09/2021. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited. Nº Ref Uniprot Proteína Péptidos identificados 1 P01024 CO3_HUMAN Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 por 162MS/MS 2 P02751 FINC_HUMAN Fibronectin OS=Homo sapiens GN=FN1 PE=1 SV=4 131 3 P01023 A2MG_HUMAN Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 128 4 P0C0L4 CO4A_HUMAN Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=1 95 5 P04275 VWF_HUMAN von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 81 6 P02675 FIBB_HUMAN Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 78 7 P01031 CO5_HUMAN Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 66 8 P02768 ALBU_HUMAN Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 66 9 P00450 CERU_HUMAN Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 64 10 P02671 FIBA_HUMAN Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 58 11 P08603 CFAH_HUMAN Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 56 12 P02787 TRFE_HUMAN Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 54 13 P00747 PLMN_HUMAN Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 48 14 P02679 FIBG_HUMAN Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 47 15 P01871 IGHM_HUMAN Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=3 41 16 P04003 C4BPA_HUMAN C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 37 17 Q9Y6R7 FCGBP_HUMAN IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 30 18 O43866 CD5L_HUMAN CD5 antigen-like OS=Homo
    [Show full text]